Pair Name | Toosendanin, Camptothecin | ||
Phytochemical Name | Toosendanin (PubChem CID: 9851101 ) | ||
Anticancer drug Name | Camptothecin (PubChem CID: 24360 ) | ||
Structure of Phytochemical |
Download
2D
MOL
3D
MOL
|
||
Structure of Anticancer Drug |
Download
2D
MOL
3D
MOL
|
Pair Name | Toosendanin, Camptothecin | |||
Disease Info | [ICD-11: 2C77] | Cervical cancer | Investigative | |
Biological Phenomena | Induction-->Autophagy | |||
Gene Regulation | Down-regulation | Activity | ATP6AP2 | hsa10159 |
Down-regulation | Expression | CTSB | hsa1508 | |
Down-regulation | Expression | CTSD | hsa1509 | |
Up-regulation | Expression | SQSTM1 | hsa8878 | |
In Vitro Model | HeLa | Human papillomavirus-related cervical adenocarcinoma | Homo sapiens (Human) | CVCL_0030 |
A-549 | Lung adenocarcinoma | Homo sapiens (Human) | CVCL_0023 | |
In Vivo Model | 1×10⁶ HeLa cells stably expressing mRFP-GFP-LC3 were suspended in 100 μL serum-free culture medium and inoculated into the left axilla. | |||
Result | These results suggest that toosendanin has the potential to be developed into an anti-cancer drug by blocking chemotherapy-induced protective autophagy. |
No. | Title | Href |
---|---|---|
1 | Toosendanin, a novel potent vacuolar-type H+-translocating ATPase inhibitor, sensitizes cancer cells to chemotherapy by blocking protective autophagy. Int J Biol Sci. 2022 Mar 28;18(7):2684-2702. doi: 10.7150/ijbs.71041. | Click |